Walleye Capital
CORT icon

Walleye Capital’s Corcept Therapeutics CORT Stock Holding History

Walleye Capital’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.68M Buy
99,847
+98,847
+9,885% +$5.97M 0.03% 543
2026
Q1 		$40.3K Sell
1,000
-179,401
-99% -$6.71M ﹤0.01% 3947
2025
Q4 		$6.28M Buy
180,401
+180,080
+56,100% +$14.1M 0.02% 978
2025
Q3 		$26.7K Sell
321
-1,711
-84% -$124K ﹤0.01% 4160
2025
Q2 		$149K Buy
+2,032
New +$147K ﹤0.01% 3564
2025
Q1 		– Sell
-460
Closed -$28K – 4367
2024
Q4 		$23.2K Buy
+460
New +$24.1K ﹤0.01% 4483
2024
Q3 		– Sell
-13,189
Closed -$429K – 5380
2024
Q2 		$429K Buy
+13,189
New +$361K ﹤0.01% 3640
2021
Q3 		– Sell
-23,514
Closed -$517K – 1627
2021
Q2 		$517K Buy
+23,514
New +$523K 0.02% 735
2020
Q1 		– Sell
-17,174
Closed -$207K – 1045
2019
Q4 		$207K Buy
+17,174
New +$239K 0.01% 1094

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Walleye Capital's CORT Position: Q2 2026 in Review

Walleye Capital increased its Corcept Therapeutics (CORT) stake by 9,885% in Q2 2026, buying an estimated $5.97M and bringing the position to 99,847 shares worth $8.68M. The position accounts for 0.03% of the portfolio, ranked #543.

Walleye Capital first reported a position in CORT in Q4 2019 and has held it in 9 quarters since. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Walleye Capital held 99,847 shares of Corcept Therapeutics worth $8.68M as of Q2 2026.
  • Walleye Capital bought 98,847 Corcept Therapeutics shares in Q2 2026, an estimated $5.97M.
  • Corcept Therapeutics made up 0.03% of Walleye Capital's portfolio in Q2 2026, its #543 holding.
  • Walleye Capital first reported a position in Corcept Therapeutics in Q4 2019 and has held it in 9 quarters since.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.